Adjuvanted pertussis vaccine (Dynavax Technologies/Serum Institute of India)
- Generic Name
- Adjuvanted pertussis vaccine (Dynavax Technologies/Serum Institute of India)
GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age
Phase 2
Not yet recruiting
- Conditions
- Streptococcus Agalactiae Infection
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 564
- Registration Number
- NCT06494475
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Phase 2
Recruiting
- Conditions
- Dermatitis Atopic
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 215
- Registration Number
- NCT06015308
- Locations
- 🇺🇸
Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama, United States
🇺🇸Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
🇺🇸Orange County Clinical Trials- Site Number : 8401271, Anaheim, California, United States
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 215
- Registration Number
- NCT03562377
- Locations
- 🇨🇦
LEO Pharma Investigational Site, Verdun, Quebec, Canada
🇺🇸Leo Pharma Investigational Site, Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath